Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
Bengaluru: Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help ...
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
LAEKNA-B (02105.HK) announced a share placing immediately after a 48% share surge yesterday (20th). Today (21st), it opened ...
Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...
LAEKNA-B (02105.HK) opened 0.94% lower today (20th) but managed to make a rebound, peaking at $14.54 with an uptick of 37%.
(Reuters) - Eli Lilly (LLY) and Hong Kong-listed Laekna (2105.HK) will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle ...
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...